Arnaud Lesegretain

Arnaud Lesegretain has been President and CEO of Orano Med since October 2024. With over 20 years of international experience in the pharmaceutical industry in R&D and commercial roles in the United States and Europe, he is passionate about innovation and the development of innovative therapies for patients. He joined the Orano Group after working at Daiichi Sankyo, where he most recently held the position of VP Oncology R&D for the TROP2-directed ADC drug. He played a key role in the approval of several drugs in the U.S., Europe, and Japan, managed a pipeline of 15 oncology programs—including ADCs, monoclonal antibodies, and small molecules—and initiated numerous strategic partnerships. Previously, he held several leadership positions in commercial and general management roles at AstraZeneca and Eli Lilly. 

Arnaud Lesegretain holds dual degrees from Harvard (MBA, MMSc) and began his studies at NEOMA.